ArticleFrontiers in immunology2025
Impact of NF-κB and reactive oxygen species on intracellular BAFF/APRIL expression in ANCA-associated vasculitis: focusing on the effect of resveratrol.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- BAFF and APRIL signaling in the B-cell lineage: implications for the pathogenesis of ANCA-associated vasculitis.Frontiers in immunology · 2026Review
- GSTA1 deficiency drives neuroendocrine differentiation via TNFRSF13B/c-FOS/CHGA axis in prostate cancer.International journal of biological sciences · 2026Article
- Innate immune cross-talk: The central role of neutrophils and macrophages in ANCA-associated vasculitis.Molecular biology of the cell · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increased expression of B-cell activation factor of the tumor necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) expression, which have been observed not only in the active phase of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) but also in remission, may cause relapse by activating autoreactive B cells that produce ANCA. It is necessary to identify a therapeutic target related to the production of BAFF and APRIL in immune cells, particularly monocytes which play a crucial role in mediating the pathological processes of AAV. We previously demonstrated the efficacy of resveratrol (RVL) in restoring the function of regulatory T cells in AAV. This study examined the effects of RVL on the expression of BAFF and APRIL in monocytes as well as their related signaling factors in patients with AAV. This study used peripheral blood mononuclear cells (PBMCs) from 35 patients with AAV and 22 healthy controls. After incubating PBMCs with and without RVL or tempol, BAFF, APRIL, reactive oxygen species (ROS), and nuclear factor-κB (NF-κB) in CD14+ cells were analyzed using flow cytometry. Additionally, BAFF and APRIL in CD14+ cells were assessed in PBMCs treated with the NF-κB inhibitor, SN50. Significantly higher BAFF, APRIL, ROS, and NF-κB expression were observed in CD14+ cells in patients with AAV than in healthy controls. In CD14+ cells treated with RVL, patients with AAV exhibited significant increases in BAFF and NF-κB expression but significant decreases in APRIL and ROS expression. In patients with AAV, there was a positive correlation between NF-κB and BAFF in CD14+ cells, regardless of RVL treatment. Patients with AAV showed a significant decrease in APRIL expression without significant changes in BAFF expression in CD14+ cells treated with tempol; whereas there was a significant decrease in BAFF and APRIL expression in CD14+ cells treated with SN50. NF-κB may be a crucial signaling factor in BAFF production. RVL induces BAFF expression in monocytes by stimulating NF-κB in AAV, while its redox reaction reduces APRIL expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.